To begin to test the antitumour activity of CUDC‐907 against prostate cancer cells, SRB assays were performed in 8 prostate cancer cell lines, including both androgen‐sensitive and castration‐resistant lines that are either AR‐positive or AR‐null. Here, AR is linked to prostate cancer.